Scarica l'app Stockscreener
17.49
0.17%
0.03
Dopo l'orario di chiusura:
17.49
Precedente Chiudi:
$17.46
Aprire:
$17.33
Volume 24 ore:
6.85M
Relative Volume:
1.24
Capitalizzazione di mercato:
$8.69B
Reddito:
$4.45B
Utile/perdita netta:
$205.00M
Rapporto P/E:
43.72
EPS:
0.4
Flusso di cassa netto:
$372.00M
1 W Prestazione:
-2.83%
1M Prestazione:
+19.14%
6M Prestazione:
+58.71%
1 anno Prestazione:
+17.70%
Intervallo 1D:
$17.33
$17.70
Intervallo di 1 settimana:
$17.33
$18.09
Portata 52W:
$8.02
$18.09
Elanco Animal Health Inc Stock (ELAN) Company Profile
Nome
Elanco Animal Health Inc
Settore
Telefono
877-352-6261
Indirizzo
2500 INNOVATION WAY, GREENFIELD
Confronta ELAN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
17.49 | 8.79B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
155.61 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.31 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.80 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
310.66 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-17 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-06-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-12-09 | Iniziato | UBS | Buy |
| 2024-12-02 | Iniziato | Leerink Partners | Market Perform |
| 2024-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-01-05 | Aggiornamento | Stifel | Hold → Buy |
| 2023-12-19 | Iniziato | Jefferies | Buy |
| 2023-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-07 | Iniziato | Exane BNP Paribas | Outperform |
| 2023-04-20 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-07-21 | Downgrade | Goldman | Buy → Sell |
| 2022-07-12 | Iniziato | Piper Sandler | Neutral |
| 2021-11-18 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-28 | Downgrade | Stifel | Buy → Hold |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-06-15 | Aggiornamento | Cleveland Research | Underperform → Neutral |
| 2021-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2021-05-11 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2021-04-15 | Iniziato | Stifel | Buy |
| 2021-03-22 | Downgrade | Gabelli & Co | Buy → Hold |
| 2021-02-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-09 | Downgrade | Argus | Buy → Hold |
| 2020-11-09 | Downgrade | Barclays | Overweight → Underweight |
| 2020-08-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-08-13 | Ripresa | Credit Suisse | Neutral |
| 2020-08-04 | Ripresa | Goldman | Buy |
| 2020-07-27 | Downgrade | Cleveland Research | Neutral → Underperform |
| 2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-10 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-11-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-23 | Iniziato | Barclays | Overweight |
| 2019-08-26 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-23 | Iniziato | Guggenheim | Neutral |
| 2019-03-18 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-03-13 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-02-12 | Iniziato | William Blair | Mkt Perform |
| 2019-01-23 | Iniziato | UBS | Sell |
| 2019-01-15 | Iniziato | Argus | Buy |
| 2018-10-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Elanco Animal Health Inc Borsa (ELAN) Ultime notizie
Exclusive Veterinary Oncology Market Report with Detailed Analysis | Zoetis Inc., Elanco, AB Science - openPR.com
Veterinary Oncology Market Growth Fueled by Rising Pet Cancer - openPR.com
Elanco Animal Health: Innovating for Sustainable Growth - AInvest
Sentiment Turns Positive on Elanco Animal Health Incorporated — Reversal Ahead2025 Retail Activity & Real-Time Market Sentiment Alerts - sundaytimes.kr
Elanco CEO Jeff Simmons: Innovation and Sustainability Drive Long-Term Growth - ACCESS Newswire
Can Elanco Animal Health Incorporated outperform under higher oil pricesEarnings Beat & Reliable Price Action Trade Plans - sundaytimes.kr
Elanco Animal Health's (NYSE:ELAN) Solid Earnings May Rest On Weak Foundations - Yahoo Finance
Leerink Partnrs Issues Negative Outlook for ELAN Earnings - MarketBeat
Elanco (ELAN) Q2 Revenue Jumps 5% - AOL.com
Elanco Animal Health stock hits 52-week high at 17.85 USD - Investing.com Canada
Piper Sandler Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price - MarketBeat
5 Insightful Analyst Questions From Elanco’s Q2 Earnings Call - FinancialContent
Nuveen LLC Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health (NYSE:ELAN) Stock Price Expected to Rise, UBS Group Analyst Says - MarketBeat
Elanco spearheads Nutrition Secure Indianapolis initiative to provide food aid - Inside INdiana Business
Dogs Vaccines Market Exclusive Report with Detailed Study - openPR.com
Cary Street Partners Financial LLC Buys New Shares in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco Animal Health Posts Robust Q2 Earnings, Exceeds Guidance with Strong Organic Growth and Innovation - AInvest
Elanco Animal Health’s Q2 Earnings Call Highlights - TipRanks
Elanco’s Q2 2025 Return to Profitability Signals Growth - Zenopa
Leerink Partners Keeps Buy Rating on Elanco Animal Health with $20 Price Target - AInvest
ELAN Q2 Deep Dive: Innovation and Execution Drive Raised Full-Year Outlook - FinancialContent
Elanco Animal Health (NYSE:ELAN) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Elanco Animal Health (NYSE:ELAN) Releases Q3 2025 Earnings Guidance - MarketBeat
Investors in Elanco Animal Health (NYSE:ELAN) From Five Years Ago Are Still Down 36%, Even After 18% Gain This Past Week - 富途牛牛
Elanco Animal Health: Piper Sandler raises PT to $18 from $12, maintains Neutral rating. - AInvest
Price Consolidation Hints at Upcoming Move in Elanco Animal Health IncorporatedReversal Alert Based on RSI Indicator Confirmed - metal.it
Arkadios Wealth Advisors Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Elanco (ELAN) Jumps 19.7% to Record High on Earnings Boost - MSN
Elanco Animal Health Surges 9% on Q2 Results and Optimistic Full-Year Forecast - AInvest
Elanco Animal Health: Analyst Sentiment Analysis and 12-Month Price Targets - AInvest
Elanco Animal Health Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Elanco Animal Health Incorporated (NYSE:ELAN) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Elanco Animal Health (ELAN) - The Globe and Mail
Elanco Animal Health (ELAN) Gets a Buy from Bank of America Securities - The Globe and Mail
Elanco Animal Health Reports Strong Q2 2025 Results - The Globe and Mail
Chart based analysis of Elanco Animal Health Incorporated trendsTrend Confirmation Scanner with Entry Focus - Newser
ICYMI: Elanco Shares Jump After 2Q Beat-and-Raise Results - iHeart
Elanco Puppy Virus Treatment Expanded With USDA Approval - InkFreeNews.com
UBS Raises PT to $19 for Elanco Animal Health Amid Bullish Outlook - AInvest
A Quick Look at Today's Ratings for Elanco Animal Health(ELAN.US), With a Forecast Between $15 to $21 - 富途牛牛
An Intrinsic Calculation For Elanco Animal Health Incorporated (NYSE:ELAN) Suggests It's 36% Undervalued - Yahoo Finance
Elanco Animal Health shares fall 1.40% premarket after beating Q2 revenue estimates and raising FY guidance. - AInvest
What institutional flow reveals about Elanco Animal Health IncorporatedStrong Buy Signal Summary with Entry Zone - Newser
Elanco Animal Health Inc (ELAN) Q2 2025 Earnings Call Highlights: Strong Pet Health Growth and ... By GuruFocus - Investing.com Canada
Elanco Animal Health 2025 Q2 Earnings Strong Performance as Net Income Surges 122% - AInvest
Elanco Raises 2025 Innovation Revenue Outlook to $720M-$800M, Signals Margin Expansion Through New Launches. - AInvest
10 Hot Stocks Making Winning Look Easy - Insider Monkey
Elanco's Q2 2025 Earnings Call: Unraveling Key Contradictions in FX Impact, Innovation Growth, and Margin Dynamics - AInvest
Elanco Animal Health Q2 2025: Innovation-Driven Growth and Accelerated Deleveraging Justify a Buy Rating - AInvest
Elanco Animal Health shares fall 1.55% after-hours despite beating Q2 revenue estimates and raising FY guidance. - AInvest
Elanco Animal Health Inc Azioni (ELAN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):